AMY SEALE: Open Payments
NPI 1689134546 · BOGALUSA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$42,001 in 223 payments from 29 companies in 2025. Trend: 2023 $1,721 · 2024 $3,211 · 2025 $42,001
Speaker / faculty: $27,286Food & beverage: $7,777Travel & lodging: $5,212Consulting: $1,726
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 56 | $20,443 |
| Ardelyx, Inc. | 43 | $14,295 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $1,287 |
| Ipsen Biopharmaceuticals, Inc | 8 | $1,258 |
| Gilead Sciences, Inc. | 15 | $1,039 |
| ABBVIE INC. | 24 | $657 |
| Janssen Biotech, Inc. | 12 | $445 |
| Regeneron Healthcare Solutions, Inc. | 7 | $318 |
| Novo Nordisk Inc | 4 | $250 |
| Abbott Laboratories | 2 | $209 |
Products named: REZDIFFRA, IBSRELA, IQIRVO, Livdelzi, TREMFYA, DUPIXENT, LINZESS, SKYRIZI.
Industry payments across LA — which companies pay providers there.
